

A Roadmap for Making the **Diagnosis in Glaucoma**

Michael Chaglasian, OD Illinois College of Optometry Chicago, IL

Eric Schmidt, OD Omni Eye Specialists Wilmington, NC

Disclosures

Michael Chaglasian, O.D. In the past 12 months Dr Schmidt has received honoraria or compensation from the following Companies:

- Allergan- Advisory Board, Speaker Bureau B+L- Advisory Board, Speaker Bureau
- Carl Zeiss
- Equinox- Research
- Heidelberg-Advisory Board
- Topcon- Consultant
- Optos- Research

Eric E. Schmidt, O.D.

- In the past 12 months Dr Schmidt has received honoraria or compensation from the following Companies:
- Aerie Advisory Board, Speaker Bureau
- 3 Allergan- Consultant, Advisory Board, Speakers Bureau
- Carl Zeiss Consultant, Advisory Board Sun- Advisory Board
- Evenovia Consultant
- 8 Kala Speakers Bureau

Topics/Sections

- 1. Who is the Glaucoma Suspect? Know the Key Risk Factors
- 2. How to evaluate the glaucomatous optic disc? Yes, you still have to do this
- 3. Perimetry: The Essentials
 No, they haven't gone away.
- 4. OCT Imaging: The Essentials Really get know your device and what it's telling (or not!)

Who is the Glaucoma Suspect?

This starts with a Risk Factor Assessment.


Risk Assessment in Clinical Practice: (quick look at 3)


- Family History
- Diabetes
- Systemic Hypertension


Risk Factors: Family History

- POAG is a multi-factorial <u>polygenetic</u> disease
- Rotterdam Study:
 - the lifetime absolute risk of glaucoma at age 80 years was found to be almost 10 times higher for individuals having relatives with glaucoma, (22.0 versus 2.4%).
 - "family history alone cannot account for the observed proportion of the disease, suggesting that <u>non-genetic factors play a significant role</u> in the overall occurrence of glaucoma."

Ophthalmol 112(9) 2005







Diabetes Summary

- The current literature does not provide a definitive link between DM and POAG.
- Vascular dysregulation in diabetes likely has a component in glaucoma disease but is likely <u>NOT a sole, initiating cause</u> of glaucoma,
- Should only be considered as a <u>modest</u> RF compared to other RFs (eg family history and CCT)

Risk Factors: Systemic Hypertension

- No definitive link to elevated BP
 - NO association in several studies
 - High Blood Pressure may be "Protective"
 - Low BP is a factor in Ocular Perfusion Pressure
 - OPP=DBP-IOP
 - Increased at OPP of <50-55 mmHg
 - OVER treatment of HTN can be an issue (BP too low)

Cardiovascular Disease no solid evidence of RF link

Rosuvastatin (Crestor) : Increased Risk OAG

	24.5		
	in the second	-	=
attani Internet	1		 _
	_	- Partie	=

"With respect to specific types of statins, participants taking rosuvastatin were more likely to suffer from glaucoma (OR 1.11, 95%CI 1.01 to 1.22). The use of other statins was not significantly associated with glaucoma onset."

Some Basic Guidelines:

Short Overview and Highlights

OHTS and	Corneal	Thickr	ness	
	l IOP's, a <u>thinn</u> oping glaucom		increased the	<u>risk</u> of
			CCT Microns	
	IOP	<555	>555-<588	>588
	>25.75	36%	13%	6%
	>23.75-<25.75	12%	10%	7%
	<23.75	17%	9%	2%
G an and a second seco				

OHTS & CCT: 3 Outcomes

<u>Thin</u> : <555 μm	High Risk (thus tre	at!)
Average: 555-588 μm	No change in Risk	(treat or monitor, use other RFs)
• <u>Thick</u> : >588 μm	Low Risk	
Applies to only to patients w	rith ocular hypertensio	<u>n</u>

Know this!

Diagnosis In The Glaucoma Suspect —When To Treat?

- Glaucoma suspects can be (broadly) categorized into two groups:
 - 1. Ocular hypertensive subjects with risk factors for the future development of glaucoma
 - These patients are addressed by OHTS data and who to treat
 - Subjects with questionable glaucomatous findings that cannot definitely be distinguished from normal
 - e.g., suspicious appearance of optic disk, RNFL/GCA or VF and

IOP that is 21 mmHg or lower

Open Angle Glaucoma Suspect


- <u>The Decision Tree:</u>
- The patient without OCT, VF or ONH damage



This may be someone with IOP >21 or <21 mmHg

Who do you treat? Options, Bias, Preferences

- Rather than a simplistic approach of treating everyone with an IOP of over 21 mmHg, treatment is held off until there is sufficient evidence of glaucoma damage at some level (OCT, VF,)
 - This is a practice philosophy that can be followed for <u>low risk</u> patients
- Or, we elect to treat those with the most significant risk factors.



Glaucoma Suspect: The Ocular Hypertensive

IOP 21-30+ mmHg with

- Normal appearing or suspicious optic nerve, But NO definitive changes!
- no visual field defects
- some risk factors
- Follow OHTS Treatment Guidelines:

Glaucoma Suspect: IOP under 21

- Management Options:
 - no single treatment plan nor guidelines, varies with every patient, must be individualized
- 1. Follow these patients every 3-6 months with observation and repeated: ONH, VF, OCT, IOP
- Wait until confirmation of true OCT/VF defect, ONH change
- 2. Or, <u>may</u> initiate therapy for those with **3** or more risk factors: Or, <u>inter</u>
 positive family history,
 C/D ratio 0.8 or greater, asymmetry of the nerve heads
 African American; diabetes, etc.
 Interfacers, fluctuating IOP

Patients Who Require Therapy:

- At any IOP
 - 1. Glaucomatous ONH Changes
 - As identified by you or via photograph, OR
 - 2. Strongly abnormal, characterstic and <u>reliable</u> OCT This must have some "clinical correlation"

 - Barely do you treat based upon this *alone* (patient has other findings) Watch out for "Red Disease"
 - 3. Characteristic/Confirmed Visual Field Loss
 - (not required for diagnosis)
- OHTN with IOP over 30 mmHg Some exceptions; eg very, thick cornea

Glaucoma diagnosis can be a very complex puzzle:



- Requirements
 - Organized, step-by-step approach Sort and organize the data
- Identify good data
- Ignore bad/unreliable data
- Confirm data when necessary Sort and organize again
- No need to rush your decision
- Individualize to your patient
- Begin therapy (later) or monitor

CASE EXAMPLE

56 yo + Fam Hx of Glaucoma Systemic HTN (lisinopril/HCTZ)

ADR DURC	190	03
20/11/2212	22	30
10172011	22	37
12/15/2018	23	25
319575/60	16	20
23/14/22/15	24	225
13/06/2014	10	- 28
1071842512	7/	-22


Discussion

OHTN? Early Glaucoma? Treat? Don't Treat? Monitor? How Frequently? Other Information? Next Steps?

What is the future risk?







Age By				LEFT EVE MEASUREMENTS		
	1#	2"	3"	-	214	3"
Unorested Intraccular Pressure	-29	10	-12	25	32	16
Control Corneal Thickness	mi	200	638	- 181	del l	-847
Vertical Cap to Disc Ratio by Contour	0.60			0.09		
Partiam Standard Deviation	17			124		

Polling Question:

What percentage risk of developing glaucoma from ocular hypertension, is considered reasonable/appropriate for starting treatment on a patient with OHTN? (by expert panel consensus)

5%
 10%
 15%
 20%

What does OHTS Risk Mean?

Expert Panel Recommendations				
< 5%	No treatment			
5-15%	Treatment optional			
>15%	Treatment recommended			

 These are suggested guidelines only, treat every case individually Must consider all and other factors (family Hx, Drance Heme, age.)



Vhen is Therapy Indicated?
 When there are other (multiple) significar Risk Factors:
CCT under 555 microns
Family History
Disc Hemorrhage
Vertical CD ratio
Low Ocular Perfusion Pressure

CASE 2

44 yo, Black, Male Last exam at Vision Center 1 month earlier "large cupping"

History and Clinical Data

- VA = 20/20 OD, OS
- Entrance Tests = normal
- Slit Lamp Exam = unremarkable
- IOP
 - 16 OD mmHg @ 9:00 AM
 - a 15 OS

- Family History
 Mother with POAG
 On topical meds
- Gonioscopy
- Open to Ciliary Body 360 OU
- Moderate Pigment

Nocturnal IOP and Glaucoma

- Most individuals spend 1/3rd of day asleep in recumbent position
- Habitual IOPs of most untreated glaucomas higher during nocturnal/sleep period than office hours
 - IOP measured sitting during day and supine position at night
- Important to understand and recognize this
 - May explain why glaucomatous damage occurring in certain individuals

Discussion

Glaucoma with IOP in the Normal Range (Normal Tension Glaucoma)

Ocular Perfusion Pressure (OPP) = <50mmHg

- The differential between arterial (diastolic) BP and IOP
 OPP = DBP-IOP
 - Ocular perfusion is regulated to maintain constant blood flow to the optic nerve despite fluctuating blood pressure and IOP
 - The major cause of reduced blood flow is thought to be secondary to vascular dysregulation in susceptible patients, resulting from abnormal/insufficient



Clinical Control of OPP

- Lower IOP improves OPP
 Remains number 1 goal !!
- Measure blood pressure on your patients
- Higher systemic BP improves OPP, but you do not necessarily want to raise BP:
 - Stroke #3 cause of death in US behind CVD & CA!
 - Avoid drugs that lower systemic BP beyond patient's desired systemic control.
 Avoid nocturnal hypotension.
 - <u>Communicate with PCP</u>


To treat or not to treat? IOP Guidelines: Randomized Clinical Trials

- IOP Is the Most Prominent and Consistent Glaucoma Risk Factor
 Important Considerations and Facts
 - Ocular Hypertension Treatment Study (OHTS)
 - CCT of less than 555 μ has higher risk
 - IOP: every 1mmHg higher (>22) increased risk by 10%
 - Early Manifest Glaucoma Trial (EMGT)
 - Every 1mmHg of IOP reduction lowers risk of progression by 10%

To treat or not to treat? IOP Guidelines: Randomized Clinical Trials

- Advanced Glaucoma Intervention Study (AGIS)
 - Another IOP related factoid:
 IOP always under 18mmHg, or keeps a mean of 12mmHg, has a lower risk of progression
- Collaborative Normal-Tension Glaucoma Study
 30% reduction of IOP reduces risk of progression
- * Note that many patients with NTG do not progress, while other with 30% IOP reduction continue to progress

Yes, you still need to look at the optic disc.



Glaucomatous Disc Features

- Descriptive terms to know : examples coming
- <u>up</u>
- increased (meaning it changed) cup-to-disc ratio or significant cup asymmetry;
- decreased or documented change in neuroretinal rim area;
- <u>notch</u> of the neuroretinal rim;
 <u>saucerization</u> of neuroretinal rim;
- <u>soucerization</u> of neuroretinal rim
 flame-shaped <u>disc hemorrhage</u>;
- name-snaped <u>disc hemorrhögi</u>
 nerve fiber layer loss;
- peripapillary atrophy
- Laminar dot sign (non-specific)

TIPS and PITFALLS

- Do not emphasize the C/D ratio
- Concentrate on the neural retinal rim
- Look for focal defects (notching) and and/or generalized thinning
- Evaluate symmetry between eyes
- Disc Hemes

- Peripapillary atrophy
- Baring of circumlinear vessels
 - Loss of NRR tissue

Examples of ONHs

CASE JM

54 YO, AA IOP IOP Range = 16- 20 OD; 16-19 OS CCT= 462 OD 468 OS CH = 8.8

Zeiss Cirrus HD-OCT RDB

Optic Disc Area


The standardow of size area for the narrowine-database eyes in discussed in the managing above. Note that the majority of mice areas which between 1.1 mm² and 2.5 mm². Therefore, normal lines will not be well defined for the populator random which do itses, and are not applied in COMDS AI upto more lined parameters measure which do itse, mice and applied in COMDS AI upto more line result and statistical parameters with obtained and the size area for the statistical parameters with a statistical parameters in the second parameters in the second parameters in the second parameters in the second parameters and the second parameters in t

р.

strong bandplane of the CRES WPL normatic abadese is as follow, 40% many, 24% Asian, 10% Alexan Assumes UVS Stapane, 1% Indian, and 2% tradicity A separated, subject of Alexan desiret for the largest data on assump 0.5 OF a m^2 source transition of Largests and stress that for scalade 1106 of 50% areas, g ac-

Management

- This patient was treated due to significant risk factors:
 - IOP high of 20 mmHg
 - Thin CCT
 - Low CH
 - OCT
 - There has been minimal progression over time
- But what can progression look like in other patients??



Clinical Background:

- BCVA: 20/20 OD and OS
- Entrance Tests: all normal
- Slit Lamp: Normal anterior segment
- Gonioscopy: Open angles, SS/CB, 360 OU

IOP
First Visit:
21 OD and 21 OS
Second Visit (AM appt)
22 OD and 22 OS
CCT / Pachymetry
481 OD and 487 OS
Corneal Hysteresis:





GLAUCOMA SEVERITY SCALE DEFINITIONS:

optic nerve changes consistent with glaucoma but <u>NO visual field abnormalities on any visual field test.</u> Moderate Stage:

- optic nerve changes AND glaucomatous visual field abnormalities in hemifield and <u>not</u> within 5 degrees of fixation.
- Severe Stage:
 optic nerve changes consistent with glaucoma AND glaucomatous visual field
 abnormalities in <u>both hemifields</u> and/or loss <u>within 5 degrees</u> of fixation in at least one
 bemifield
- If both of the patient's eyes are glaucomatous, code for the more severe stage of the two eyes.

American Glaucoma Society






Perimetry: The Essentials


- Required at baseline for all patients (std of care) but perhaps best clinical usefulness is for middle and late stage disease
- Using software for Progression Analysis
- Faster Testing Options: new SITA Faster SITA Faster testing takes about two-thirds of the time required by SITA Fast and about half the time required by SITA Standard.
- Central Visual Fields and Glaucoma
 - 50% of retinal ganglion cells are found within 4.5mm of fovea
 - Macula region comprises only 10% of overall visual field area though it is responsible for 60% of area of visual cortex
 - 10-2 grid pattern is best for detecting small, central defects


- **Perimetry: The Essentials**
 - Central VF Testing (cont.) Rationale (Don Hood papers) Macular Zone Vulnerability
 - How and when use 10-2 VFs or the new

24-2C (adds 10 Central test points):

- Good Test Takers, Younger patients
- Minimal to no defects on 24-2
- OCT Macula/Ganglion Cell scan is abnormal
- High Risk Patients








How and when use 10-2 VFs

- Good Test Takers, Younger patients
- Minimal to no defects on 24-2
- OCT Macula/Ganglion Cell scan is abnormal
- High Risk Patients
- Be Selective for High Risk Patients



- - Runs new SITA-Faster algorithm
 - Test time ~2.5 minutes

 - Can be integrated with other tests for Progression Analysis Can have high False Positives (>15%)
 - Best for reliable/good VF test takers May not compare exactly to other tests
 - May not be best for baseline tests Note both baseline tests must be the same in order to start GPA

SITA Faster Considerations

Very short testing time (<2min)</p>

Higher False Positive Rate

- Give better, more clear instructions to the patient to be more discriminating when responding
- Excellent VF test for "good test takers"
 Allows for more frequent tests to be completed
- Not directly comparable on a "one to one" comparison Obtain a series of tests with Faster


¹ Bar, d. L. Samo, a parallel & second structure of the second structure	in a
Television and the second	-
And Andrew Providence	and the
	- E
24.4	
Litra a l	
International Contractions	

★


OCT, also Essential

Review of Key Points and Demonstrated on Case Examples

Tip #1: **Know your OCT and its Report** (too) Many Options!!




Tip #2: Assure a Quality Image without an Artifact







Segmentation Failure:

Repeat the scan, should not use in management.







Tip #3: Understand Structure-Function Classic Confirmation vs. Normal Variability

Use this to confirm the presence of glaucoma vs other disease or artifact.

